MyMD Pharmaceuticals Enrolls First Client in Stage 2 Medical Trial of MYMD-1 as a Treatment for Delaying Aging as well as Expanding Healthy And Balanced Life Expectancy

MyMD Pharmaceuticals, Inc. MYMD stock price (” MyMD” or “the Firm”), a medical stage pharmaceutical firm committed to prolonging healthy and balanced life expectancy, today introduced that the initial individual has actually been enrolled in the Firm’s Stage 2 scientific test of lead candidate MYMD-1, an oral immune regulatory authority medication, as a therapy for delaying aging as well as expanding healthy and balanced life expectancy.

The main endpoint for the Stage 2 double-blind, placebo-controlled medical trial is to attain a reduction in the flowing degrees of (TNF-α), lump death variable receptor I (TNFRI) and also IL-6. TNF-α and also IL-6 are the proteins in the body that trigger inflammation and also aid activate the process of aging. The additional actions of the test will be the safety and security, tolerability, and also pharmacokinetics in this population of patients.

” In a Phase 1 professional trial of MYMD-1, we showed the medicine’s statistically substantial effectiveness in minimizing degrees of TNF-α, a principal in triggering pathological aging, in the blood. The FDA has actually approved TNF-α reduction as the key endpoint for our Stage 2 research, which our team believe settings us well for an effective Phase 2 outcome,” stated Chris Chapman, M.D., President, Director as well as Chief Medical Policeman of MyMD. “The initiation of person enrollment in this research study advancements our goal to reduce the aging process, avoid loss of muscle mass cells in aging, limit frailty, as well as extend healthy life expectancy.”

MyMD has mentioned that there are no FDA-approved drugs for dealing with aging problems as well as prolonging healthy and balanced life expectancy human beings, a market anticipated to be a minimum of $600 billion by 20251 according to a major investment bank. TNF-α blockers are one of the most prescribed drugs by earnings, an international market of around $40 billion annually,2 as well as, according to Nature Aging journal,3 a downturn in aging that would certainly raise life span by one year is worth $38 trillion and also by ten years deserves $367 trillion.

In addition to aging, MYMD-1’s distinctive action in controling the body immune system and also dealing with chronic swelling is being developed for the therapy of autoimmune condition, including rheumatoid joint inflammation (RA), numerous sclerosis (MS), diabetic issues, as well as inflammatory digestive tract disease.

” We intend to begin creating methods for a Phase 2 pilot study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman kept in mind. “The increasing frequency of rheumatoid arthritis and various other autoimmune as well as inflammatory conditions are driving need for TNF inhibitors like MYMD-1, and also our company believe our by mouth carried out medication with extremely reduced toxicity would be disruptive to the $60 billion market for RA if accepted by the FDA for this indicator.”

Rheumatoid arthritis impacts about 40 million individuals around the world.4.

Concerning MYMD-1.

Initially developed for autoimmune illness, MYMD-1’s main purpose is to slow the aging procedure, prevent sarcopenia as well as frailty, and also expand healthy and balanced life expectancy. Because it can go across the blood-brain obstacle as well as access to the main nerves (CNS), MYMD-1 is likewise placed to be a possible treatment for brain-related disorders. Its device of activity and efficiency in illness including several sclerosis (MS) and thyroiditis have been studied with cooperations with a number of academic establishments. MYMD-1 is additionally showing assurance in pre-clinical researches as a possible therapy for article- COVID-19 issues and as an anti-fibrotic and also anti-proliferation healing.

MYMD-1 has revealed effectiveness in pre-clinical studies in managing the body immune system by executing as a careful inhibitor of lump necrosis factor-alpha (TNF-α), a vehicle driver of persistent swelling. Unlike various other therapies, MYMD-1 has actually been displayed in these pre-clinical researches to selectively obstruct TNF-α when it becomes overactivated in autoimmune diseases as well as cytokine storms, but not block it from doing its normal task of being a very first -responder to any kind of routine kind of modest infection. MYMD-1’s ease of oral dosing is an additional differentiator contrasted to presently available TNF-α blockers, every one of which require delivery by shot or mixture. No approved TNF prevention has actually ever been dosed orally. Furthermore, the drug is not immunosuppressive and has actually not been revealed to trigger the severe adverse effects usual with traditional therapies that deal with inflammation.

Concerning MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a medical phase pharmaceutical firm devoted to extending healthy life-span, is focused on developing two novel healing systems that deal with the root causes of condition rather than only dealing with the signs and symptoms. MYMD-1 is a medicine platform based upon a clinical phase tiny molecule that controls the immune system to control TNF-α, which drives persistent swelling, as well as other pro-inflammatory cell signaling cytokines. MYMD-1 is being created to delay aging, rise durability, as well as deal with autoimmune illness and COVID-19- connected anxiety. The Business’s second medicine platform, Supera-CBD, is being established to deal with chronic pain, dependency and also epilepsy. Supera-CBD is an unique artificial by-product of cannabidiol (CBD) and also is being established to address and also surpass the rapidly expanding CBD market, that includes both FDA authorized medicines and also CBD items not currently managed as drugs. For more information, go to www.mymd.com.

Comments are closed.